Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
Prior Studies Demonstrate Frequency of Prostate Motion, Supporting Need for the CyberKnife System's Real-Time Tracking to Spare Surrounding Sensitive Structures
The study, led by
The authors refer to the findings as "highly encouraging," but remind readers that longer follow-up is required "to confirm durable biochemical control rates and low late toxicity profiles."
"The evidence in Dr. King's study shows a lot of promise for prostate
cancer patients around the world who are looking for a shorter, less invasive
and more convenient course of treatment," said
Because the prostate can move unpredictably due to bowel gas or filling of the bladder, it is important that prostate motion is assessed and corrected for throughout treatment to allow for accurate radiosurgery treatment. Recent studies have confirmed that the prostate experiences rapid and unpredictable motion of as much as five millimeters in as few as 30 seconds, meaning that radiosurgery delivery must recognize and correct for even the slightest motion to ensure the target receives adequate dose and the surrounding sensitive structures, such as the rectum, bladder, urethra and nerves, are maximally spared.
In
Conventional IGRT therapies and other "rapid" radiation delivery techniques typically provide imaging limited to only pre-treatment set-up and therefore lack the ability to recognize motion that occurs during treatment delivery. With such conventional techniques there is - at minimum - a two minute delay in the time between when the image is captured and the beam delivery is completed. With an image age of two minutes or more, potential motion that has proven to occur in as few as 30 seconds remains undetected, potentially resulting in inferior targeting accuracy and a heightened risk of surrounding tissue complications.
Another study, led by the
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
clinical studies, regulatory review and approval, and commercialization of
products are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements speak only as of the date the statements are made
and are based on information available at the time those statements are made
and/or management's good faith belief as of that time with respect to future
events. You should not put undue reliance on any forward-looking statements.
Important factors that could cause actual performance and results to differ
materially from the forward-looking statements we make include: market
acceptance of products; competing products, the combination of our products
with complementary technology; and other risks detailed from time to time
under the heading "Risk Factors" in our report on Form 10-K for the 2008
fiscal year, as updated in our Form 10-Q filed on
SOURCE
CONTACT:
Senior Manager,
Public Relations of
+1-408-789-4234,
stomei@accuray.com;
or
of Schwartz
Communications,
+1-415-817-2545,
bdonahue@schwartz-pr.com,
for
Web Site: http://www.accuray.com